A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
DOI: 10.1634/theoncologist.2017-0665
Afshin Eli Gabayan,
Albert Assad,
Daniel D. Von Hoff,
Gregory L. Beatty,
Huiling Zhen,
Julie Switzky,
Nikhil Uppal,
Ross Donehower,
Safi Shahda,
Steven J. Cohen,
Thaddeus Beck
Abstract:
Full-Text
